Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided updates on its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI), as well as its regulatory pathway and listing status. The company has dosed nine participants across three active Australian clinical sites: Alfred Health, Mackay, and Royal Adelaide Hospital. These sites are part of an ongoing study evaluating the safety and feasibility of ONP-002, delivered via the company's proprietary intranasal platform.
The company has also received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package, submitted in July 2026. Oragenics is currently reviewing the FDA's feedback and remains on track to submit an Investigational New Drug (IND) application by the end of 2026. This regulatory progress is a critical step toward advancing ONP-002 into U.S. clinical trials, with a Phase 2b study planned to follow the Australian trials.
In a separate development, Oragenics received a deficiency letter from NYSE American on Aug. 26, 2026, related to stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance. Oragenics intends to submit its plan within the required timeframe. If accepted, the plan would allow the company to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
These updates highlight Oragenics' dual focus on advancing its lead candidate and securing its financial standing. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, underscoring the broader impact of its technology. For more information, visit the company's newsroom at https://nnw.fm/OGEN.
